Does Gabapentin Actually Reduce Inflammation?

Gabapentin was not designed as an anti-inflammatory drug, and it is not prescribed as one. It works primarily by blocking calcium channels in the nervous system to quiet overexcited nerves, which is why doctors use it for epilepsy, nerve pain, and sometimes anxiety. Yet a growing body of laboratory and animal research shows that gabapentin can dampen several inflammatory pathways, lowering key inflammatory markers in specific experimental settings. Whether that translates into meaningful anti-inflammatory effects in people remains an open and genuinely complicated question, partly because a handful of studies have found gabapentin doing the opposite and ramping inflammation up.

What Gabapentin Was Built to Do

Gabapentin was originally synthesized to mimic the brain chemical GABA, but it turned out not to bind to GABA receptors at all. Instead, its main action is binding to the alpha-2-delta-1 subunit of voltage-gated calcium channels in the central nervous system, which reduces the excitatory calcium influx that drives pain signaling and seizure activity.¹ That calcium-channel binding is the mechanism behind its approved uses. Everything else the drug does, including any effect on inflammation, is secondary or downstream.

But gabapentin turns out to be busier than its original designers expected. A 2024 review catalogued at least seven distinct pharmacological activities, including blocking calcium influx, reducing glutamate release, enhancing GABA synthesis, and, relevant here, inhibiting the activation of NF-kB, a master switch for inflammatory gene expression, and stimulating the purinergic adenosine A1 receptor, which has known anti-inflammatory and wound-healing properties.² So the drug has multiple avenues through which it could, in theory, tamp down inflammation. The question is how strong those effects are in practice and where in the body they matter.

How Gabapentin Quiets Immune Cells in the Spinal Cord

Some of the most consistent anti-inflammatory evidence for gabapentin comes from studies of microglia, the immune cells that patrol the brain and spinal cord. When microglia become chronically activated, they pump out inflammatory signaling molecules that amplify pain. In rats with inflammatory arthritis, daily gabapentin injections suppressed spinal microglial activation, reduced levels of a chemokine called CX3CL1, and blocked the development of heightened pain sensitivity.³ A separate study in diabetic rats found the same pattern: gabapentin reduced microglial activation in the spinal cord’s dorsal horn, and that reduction correlated with less pain-related behavior.⁴

In cultured spinal cord cells exposed to bacterial toxins that trigger inflammation, gabapentin significantly reduced the release of interleukin-6, a key inflammatory signaling molecule. It also lowered the expression of IL-6 at the gene level.⁵ Interestingly, that same study found that gabapentin did not alter activation of NF-kB in those particular spinal cord cultures, which hints that the drug may use different anti-inflammatory routes in different tissue types.

Another dimension of gabapentin’s central nervous system effects involves neutrophils, a type of white blood cell. In diabetic rats, researchers found that neutrophils infiltrated the spinal cord tissue itself, and gabapentin treatment prevented this infiltration while also reducing the adhesion molecule L-selectin that helps neutrophils cross into tissues.⁶ So within the spinal cord, gabapentin appears to reduce inflammation by multiple routes: calming microglia, lowering inflammatory cytokines, and blocking immune cell recruitment.

The NF-kB Connection

NF-kB is a protein complex that, once switched on, drives the production of dozens of inflammatory molecules. Several studies have found gabapentin can interfere with this pathway, though the evidence comes from different experimental systems. In human glioblastoma cells exposed to substance P (a pain-related neuropeptide), gabapentin inhibited the phosphorylation and nuclear movement of NF-kB, which in turn reduced production of inflammatory interleukins IL-6 and IL-8.⁷

In a rat model of sepsis-induced liver damage, gabapentin reduced levels of pro-inflammatory mediators, suppressed NF-kB gene expression, and decreased the activity of MAP kinase signaling proteins ERK1/2 and JNK1/2, all of which feed into the inflammatory cascade.⁸ A similar NF-kB suppression showed up in rats with brain hemorrhage, where gabapentin reduced brain tissue injury, lowered circulating IL-6 levels, and appeared to work through a PPARγ-NF-kB pathway.⁹

These results are striking, but a caveat is important: sepsis, brain hemorrhage, and stimulated cell cultures are extreme inflammatory states. Whether gabapentin meaningfully suppresses NF-kB in the everyday low-grade inflammation that characterizes chronic pain conditions remains unknown.

Animal Models of Acute Inflammation

The classic way to test whether a drug fights inflammation in a living animal is to inject an irritant like carrageenan into a paw and measure the resulting swelling. In mice pretreated with gabapentin, paw swelling from carrageenan or dextran was significantly reduced. The same dose also blocked swelling triggered by histamine, serotonin, bradykinin, and prostaglandin E2, which suggests gabapentin was interfering broadly with several inflammatory mediators rather than just one.¹⁰ Gabapentin also lowered neutrophil migration, reduced the enzyme myeloperoxidase (a marker of neutrophil activity), and decreased the pro-inflammatory cytokines IL-1β and TNF-α in the peritoneal fluid.

A separate rat study using the same carrageenan paw model confirmed that gabapentin reduced swelling at six hours and lowered IL-1β and TNF-α levels in a manner comparable to diclofenac, a standard anti-inflammatory drug. However, gabapentin was less effective than diclofenac at raising IL-10, an anti-inflammatory cytokine that helps resolve inflammation.¹¹ That distinction matters: gabapentin may be better at suppressing the pro-inflammatory side than at actively promoting resolution.

When Gabapentin Made Inflammation Worse

Not every study paints a flattering picture. In rats with chronic nerve constriction injuries, oral gabapentin at 60 mg/kg significantly increased myeloperoxidase, TNF-α, and IL-1β levels in the injured nerve. At both 60 and 120 mg/kg, gabapentin also worsened carrageenan-induced paw swelling and boosted macrophage migration in the peritoneum, compared to controls.¹² The researchers still confirmed that gabapentin reduced pain behavior, which led them to suggest the drug’s pain relief operates through a central nervous system mechanism independent of, and possibly despite, its peripheral inflammatory effects.

This is a genuinely puzzling result, and it challenges any simple narrative that gabapentin is “anti-inflammatory.” The conditions matter enormously. In an acute chemical irritation model, gabapentin suppresses swelling and cytokines. In a chronic nerve injury model, it can amplify peripheral inflammation while still reducing pain through its brain and spinal cord effects. The underlying biology likely differs: chronic nerve injury involves a different immune cell landscape and different signaling patterns than a carrageenan injection, and gabapentin’s net effect may tip in different directions depending on which immune cells are dominant and which pathways are already active.

Pain Relief Without Reducing Swelling

In several arthritis models, gabapentin clearly reduces pain-related behavior but does not necessarily reduce the joint swelling itself. In mice with adjuvant-induced inflammatory arthritis, gabapentin significantly lowered pain responses and reduced inflammatory cytokines (IL-1, IL-6, TNF-α) in the foot and dorsal root ganglia. But the researchers specifically noted that ionotropic glutamate receptor antagonists produced good pain relief “without altering foot swelling,” suggesting the pain reduction was driven by nerve-level changes rather than by resolving the joint inflammation.¹³

A study using antibody-induced arthritis models found something complementary. Gabapentin produced a “place preference,” meaning arthritic mice chose to spend time in a compartment associated with the drug, suggesting it relieved ongoing discomfort. The traditional anti-inflammatory ketorolac also produced place preference during the early inflammatory phase but lost its effect later on, while gabapentin continued to work, consistent with a neuropathic pain component that persists after acute inflammation recedes.¹⁴

This distinction between pain and inflammation is crucial for anyone wondering whether gabapentin can substitute for an anti-inflammatory drug. In arthritis-like conditions, gabapentin relieves pain effectively but appears to leave the underlying tissue inflammation partially or fully intact. It is calming the nervous system’s response to inflammation more than it is extinguishing the inflammation itself.

Neuropeptides and the Sensitization Catch

One of gabapentin’s more interesting anti-inflammatory effects involves neuropeptides like substance P and CGRP, molecules released by sensory nerves that not only signal pain but also promote local inflammation by dilating blood vessels and recruiting immune cells. Gabapentin reduced the release of these neuropeptides from rat spinal tissues, but only after prior inflammation or activation of a specific enzyme (protein kinase C). In non-inflamed tissue, gabapentin had no effect on neuropeptide release.¹⁵

This is a revealing finding. It means gabapentin’s anti-inflammatory potential may be state-dependent: the drug does more when the system is already inflamed and sensitized, and less when things are calm. That could partly explain the contradictory results across studies. The drug’s inflammatory effects likely depend heavily on what kind of inflammation is present, how long it has been going on, and which tissues are involved.

A follow-up study confirmed that gabapentin reduced substance P release in the spinal cord at higher doses (both when delivered directly into the spinal fluid and when given systemically), but it could not block the effect of substance P that was directly injected, suggesting it works upstream of neuropeptide action rather than blocking the receptor.¹⁶

Macrophage Polarization After Heart Attack

One of the more unexpected areas of gabapentin inflammation research involves the heart. In a 2024 rat study of myocardial infarction, gabapentin shifted the balance of macrophages in the damaged heart tissue. It reduced the expression of M1 macrophage markers (the pro-inflammatory type) and the cytokines TNF-α and IL-1β, while increasing M2 macrophage markers (the tissue-repair type) including arginase-1, CD163, and the anti-inflammatory cytokines IL-10 and TGF-β.¹⁷ The researchers linked this effect to a PPARγ-mediated pathway.

If that macrophage-polarization effect holds up in further research, it would represent a genuinely interesting form of immune modulation, not just suppressing inflammation but redirecting it toward repair. But this is one animal study, and cardiac remodeling after a heart attack is a very specific context. Nobody should read this as a reason to take gabapentin for heart health.

Sex Differences in Gabapentin’s Inflammatory Effects

A 2024 mouse study of repeated mild traumatic brain injury uncovered a stark sex difference. Male mice with brain injuries showed a place preference for gabapentin, meaning the drug relieved their ongoing discomfort. Female mice with the same injuries showed the opposite response: gabapentin produced a place aversion, suggesting it was unpleasant rather than relieving.¹⁸ When the researchers treated the mice with minocycline (an antibiotic that also suppresses microglial inflammation), it blocked gabapentin’s reinforcing effect in males and also blocked the aversive effect in females, suggesting that inflammation itself was driving the sex-dependent response to gabapentin.

This finding hints that gabapentin’s interaction with neuroinflammation may work differently in male and female nervous systems. The underlying biology likely involves sex differences in microglial signaling, which other research has documented. For anyone wondering why gabapentin seems to work well for some people’s pain and poorly for others, sex-based differences in neuroinflammation could be part of the answer, though human data confirming this are still lacking.

Combining Gabapentin with Traditional Anti-Inflammatory Drugs

If gabapentin has some anti-inflammatory properties and NSAIDs have strong ones, does combining them produce extra inflammation reduction? The evidence suggests the synergy is mostly on the pain side, not the swelling side. In rats with carrageenan-induced inflammation, mixtures of gabapentin and naproxen interacted synergistically to reverse thermal hyperalgesia (heat sensitivity), particularly at ratios weighted toward gabapentin. But when the researchers looked at paw swelling, no combination of gabapentin and naproxen reduced edema more than either drug alone.¹⁹

Newer work on combining gabapentin with ketoprofen (another NSAID) in a co-crystal formulation found “supra-additive” effects on pathways related to neuropathic pain and gastric protection.²⁰ Again, the synergy was framed around pain modulation and tolerability rather than inflammation reduction per se. The practical upshot: combining gabapentin with an NSAID may let you get better pain control, potentially at lower NSAID doses, but gabapentin is not amplifying the anti-inflammatory effect in a straightforward way.

What Gabapentin Does to the Immune System During Surgery

Surgery triggers a stress response that reshapes immune function, temporarily suppressing some arms of immunity while activating inflammation. In women undergoing hysterectomy, gabapentin given perioperatively significantly lowered cortisol levels 24 hours after the operation compared to placebo and reduced catecholamine (stress hormone) concentrations. It also shifted the balance of immune cell subsets: the proportions of certain T cells (CD3+ and CD3+CD4+ cells) were lower in the gabapentin group a day after surgery, while B cells (CD19+) were higher.²¹

Whether those immune shifts are beneficial or merely incidental is not clear from a single study. The cortisol reduction is interesting because cortisol itself is a powerful anti-inflammatory hormone, yet the overall profile suggests gabapentin was broadly dampening the surgical stress response. This is one of the few human data points on gabapentin and inflammation, and it comes from a very specific clinical window rather than from chronic use.

A Separate Role in Synapse Formation

One of gabapentin’s biological effects that gets overlooked in the inflammation conversation involves its ability to block the formation of new excitatory synapses. The alpha-2-delta-1 protein that gabapentin binds to turns out to also be the receptor for thrombospondins, proteins released by astrocytes that promote synapse formation. Gabapentin antagonizes thrombospondin binding and powerfully inhibits excitatory synapse formation both in cell culture and in living animals.²² This matters because after nerve injury, a burst of new synapse formation can rewire pain circuits in ways that make pain persist long after the original injury heals. Blocking that rewiring may be part of how gabapentin provides lasting pain relief, and it is mechanistically distinct from either its calcium-channel effects or its anti-inflammatory effects.

It also offers a clue about why gabapentin’s pain relief often exceeds what you would predict from its modest anti-inflammatory activity alone. The drug is working on multiple fronts: calming calcium channels, reducing neuropeptide release in sensitized states, suppressing microglial activation centrally, and preventing aberrant synapse formation. Inflammation reduction is one thread in a multi-strand rope, probably not the strongest one.

Where the Evidence Stands Overall

A 2025 systematic review of preclinical studies on gabapentin’s immunomodulatory and anti-inflammatory effects identified thirteen in vitro and in vivo studies from 2015 to 2025 that evaluated the drug’s impact on inflammatory signaling, cytokine production, immune cell activity, and tissue inflammation. The review found that gabapentin demonstrated potential modulation of inflammatory responses across models of neuropathic pain, neuroinflammation, uveitis, and sepsis, primarily through NF-kB and MAPK inhibition, PPARγ signaling, and activation of the Nrf2/HO-1 antioxidant pathway.²³ Thirteen studies over a decade is not a deep evidence base, and the review covered only preclinical work, meaning no controlled human trials focused specifically on gabapentin’s anti-inflammatory properties were included.

The practical reality is this: if you are taking gabapentin for nerve pain or epilepsy, some of the drug’s benefit may come from dampening inflammation in the spinal cord and brain. But gabapentin is not a replacement for an NSAID, a corticosteroid, or any other drug specifically designed to fight inflammation. Its anti-inflammatory effects are inconsistent across tissues, context-dependent, sometimes paradoxically pro-inflammatory in peripheral nerve injury settings, and supported almost entirely by animal and cell-culture data. Researchers are interested in these properties, and the cardiac and neuroinflammation findings are genuine leads for future clinical investigation. For now, though, gabapentin’s relationship with inflammation is best described as a side effect of its primary mechanism rather than a reliable therapeutic action in its own right.